摘要
目的探讨瑞舒伐他汀对急性心肌梗死(AMI)后心室重构及心功能的影响。方法 74例未行冠状动脉介入治疗、血脂正常的AMI患者,随机分为治疗组41例和对照组33例。治疗组于常规治疗基础上加服瑞舒伐他汀10mg,睡前服用,1次/d,对照组仅给予常规治疗。于治疗后2周、12周检测超敏C反应蛋白(hs-CRP)、左室射血分数(LVEF)、左室舒张末期容积(LVEDV)和左室收缩末期容积(LVESV)。结果治疗组治疗12周hs-CRP、LVEDV、LVESV均较治疗2周和对照组均降低,LVEF升高,差异均有统计学意义(P<0.05),对照组治疗12周与治疗2周比较差异无统计学意义(P>0.05)。结论瑞舒伐他汀具有抗动脉粥样硬化及逆转作用,可有效抑制心室重构,从而改善患者心功能及远期预后。
Objective To investigate the effects of rosuvastatin on ventricular remodeling and ventricalar function after acute myocardial infarction（AMI）.Methods 74 normal lipidemia AMI patients without percutaneous coronary intervention （PCI）were randomly divided into rosuvastatin treatment group （treatment group,n=41）and routine treatment group（control group,n=33）.The control group was given routine therapy.The treatment group took rosuvastatin 10mg / d in addition to routine therapy.The hs-CRP,LVEF,LVEDV and LVESV were measured after 2-week and 12-week treatment of AMI.Results In treatment group,the levels of hs-CRP,LVEF,LVEDV and LVESV were improved significantly after 12-week treatment compared with after 2-week treatment and the control group,the differences were statistically significant （P0.05）,however, which were not changed significantly in control group （P0.05）.Conclusion Our results suggested that rosuvastatin could delay the proceeding of atherosclerosis,inhibit ventricular remodeling,improve ventricalar function and long-term prognosis.
出处
《临床合理用药杂志》
2013年第23期3-4,共2页
Chinese Journal of Clinical Rational Drug Use
关键词
瑞舒伐他汀
急性心肌梗死
心室重构
心功能
Rosuvastatin
Acute myocardial infarction
Ventricular remodeling
Ventricular function
